Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer

ClinicalTrials.gov ID: NCT02737787

Public ClinicalTrials.gov record NCT02737787. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 2:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Study of Concomitant WT1 Analog Peptide Vaccine or NY-ESO-1 Overlapping Peptides Vaccine in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to test the safety of a combination of an investigational WT1 vaccine and another drug called nivolumab. This is the first time that the WT1 vaccine and nivolumab are being used in combination. Also, to test the safety of a combination of an investigational NY-ESO-1 vaccine and another drug called nivolumab.

Study identification

NCT ID
NCT02737787
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Enrollment
11 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 2016 (Actual)
Primary completion
Apr 6, 2023 (Actual)
Completion
Apr 6, 2023 (Actual)
Last update posted
Apr 7, 2023

2016 – 2023

United States locations

U.S. sites
7
U.S. states
2
U.S. cities
7
Facility City State ZIP Site status
Memorial Sloan Kettering Cancer Center (All Protocol Activities) Basking Ridge New Jersey — —
Memorial Sloan Kettering Monmouth (All Protocol Activities) Middletown New Jersey 07748 —
Memorial Sloan Kettering Bergen (All Protocol Activities) Montvale New Jersey 07645 —
Memorial Sloan Kettering Commack (All Protocol Activities) Commack New York 11725 —
Memorial Sloan Kettering Westchester (All Protocol Activities) Harrison New York 10604 —
Memorial Sloan Kettering Cancer Center (All Protocol Activities) New York New York 10065 —
Memorial Sloan Kettering Nassau (All protocol activities) Rockville Centre New York 11553 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02737787, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 7, 2023 · Synced Oct 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02737787 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →